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INTRODUCTION
Giant cell tumor of bone (GCTB) is a histologically benign, locally aggressive osteolytic intramedullary lesion composed of rounded mononuclear histiocytic cells and spindle-shaped stromal cells of mesenchymal origin which are the true neoplastic component of the lesion and which promote the formation of the eponymous giant cells that are responsible for the extensive bone resorption characteristic of GCTB. 1,2 GCTB typically affects the metaphyses of the long bones of young adults and skeletally mature adolescents, females slightly more often than males, and accounts for 5% of all bone tumors and 20% of benign bone tumors. It has an unpredictable natural course with metastases in 2%-3%, mainly to the lungs. 3 Surgery is the mainstay of treatment, usually intralesional curettage being the method of choice, supplemented with local adjuvants, aiming to minimize the risk of recurrence. Advanced understanding of the biology of GCTB proved that signaling through the receptor activator of nuclear factor kappa B (RANK) expressed by the giant cells and its ligand (RANKL) expressed by the stromal cells is critical to tumor growth and osteolysis. [4] [5] [6] [7] In 2013, the Food and Drug Administration (FDA) extended the approval of denosumab for use in patients with GCTB that is unresectable or where surgical resection is likely to result in severe morbidity, followed by the European Medicines Agency (EMA). 6 
CASE REPORT
A (Fig. 1A) . (Fig. 1B) . On MRT, the signal was heterogeneous, low in T1 and high in T2 with limited cystic areas (Fig. 1C) (Fig. 2A) (Fig. 2B) (Fig. 2C) 
Computed tomography showed an isodense lesion with scalloping of the inner cortex that was very thin and expanded

DISCUSSION
In the present case, the patient had an excellent response to denosumab treatment prior to surgery with a clear downstaging effect. Following denosumab therapy, the resected specimen contained no osteoclast-type giant cells and new bone formation was observed when compared with the incisional biopsy. Neoadjuvant denosumab therapy created a situation where safe marginal resection could be performed instead of more extensive surgery which would probably impair limb function, given the anatomical location of the tumor. There were no complications or evidence of metastatic, residual, or local recurrent disease one year after initiation of treatment with denosumab. However, different adverse events have been reported in the literature after denosumab treatment: hypercalcemia, infection, possible malignant transformation, osteonecrosis of the jaw, and increased human chorionic gonadotropin concentration. [8] [9] [10] In spite of this, Dubory et al. 8 stated that the use of denosumab could be accepted as safe. Usually, after denosumab treatment, RANKL expression and osteoclast-type giant cells fully disappear and new bone is formed but a few neoplastic stroma cells persist thus increasing the risk of local recurrence. Therefore, additional surgical treatment is mandatory. 8,10 Dubory et al. 8 pointed out that the effect of denosumab reaches a peak in the first six months and plateaus later on.
In conclusion, denosumab is effective as neoadjuvant treatment in cases of aggressive GCTB because it reduces the volume of tumor tissue and allows for safe marginal surgery and lower recurrence rates. 
